Journal of Investigational Allergology and Clinical Immunology最新文献

{"title":"Delayed Anaphylaxis to Multiple Antihistamines and the Use of Basophil Activation Testing for Diagnosis.","authors":"Monica C Patterson, Emily M Mulcahy, Troy Wanandy, Wun Y Lau, Thanh-Thao A Le","doi":"10.18176/jiaci.1137","DOIUrl":"10.18176/jiaci.1137","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"157-159"},"PeriodicalIF":4.8,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146144522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Future Perspectives for Artificial Intelligence in Allergy: Advances in Diagnosis, Monitoring, and Personalized Care.","authors":"Esther Moreno, Vidal Moreno, Belén Curto, Ignacio Dávila","doi":"10.18176/jiaci.1154","DOIUrl":"10.18176/jiaci.1154","url":null,"abstract":"<p><p>Artificial intelligence (AI) is significantly transforming the specialty of allergy by offering novel tools for diagnosis, risk prediction, disease monitoring, and personalized care. This narrative review comprehensively explores key advances in the application of AI techniques-expert systems, machine learning, deep learning, and natural language processing-across various allergic diseases such as asthma, anaphylaxis, atopic dermatitis, food allergy, allergic rhinitis, eosinophilic esophagitis, and drug hypersensitivity reactions. Despite these advancements, several challenges persist, including model interpretability, external validation, and ethical and regulatory barriers. Nonetheless, AI holds strong potential to enhance diagnostic efficiency, therapeutic precision, and patient outcomes. This review presents an updated perspective on the state of the art of AI in allergy, highlighting both its achievements and ongoing challenges.</p>","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"85-99"},"PeriodicalIF":6.6,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147437084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Dupilumab on Restoring Tolerance to Nonsteroidal Anti-Inflammatory Drugs in Patients With Aspirin-Exacerbated Respiratory Disease.","authors":"Isamar De Agrela-Mendes, África Serrano-Sánchez, María D Moreno-Llorente, Valentín Lopez-Carrasco, Javier Domínguez-Ortega, Santiago Quirce, Leticia De Las Vecillas","doi":"10.18176/jiaci.1136","DOIUrl":"10.18176/jiaci.1136","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"143-145"},"PeriodicalIF":4.8,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145726746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Strongyloides stercoralis Infection, Imatinib, and DRESS.","authors":"Öner Özdemir","doi":"10.18176/jiaci.1129","DOIUrl":"10.18176/jiaci.1129","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"165-166"},"PeriodicalIF":4.8,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145670464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breaking the Allergic Paradigm: Inhibition of BTK With Acalabrutinib Prevents IgE-Mediated Carboplatin-Induced Anaphylaxis.","authors":"Javier Pereira-González, Laura Viñas-Giménez, Johana Gil-Serrano, Paula Galván-Blasco, Teresa Rubio-Foncuberta, Aina Bruch-Tàrrega, Alex Ruiz-Carrasco, Mar Guilarte, Victoria Cardona, Moisés Labrador-Horrillo","doi":"10.18176/jiaci.1162","DOIUrl":"10.18176/jiaci.1162","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"146-149"},"PeriodicalIF":4.8,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145960710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Eosinophilic Esophagitis Doubles in Less Than a Decade: A Population-Based Study in 2 Regions of Spain.","authors":"Ángel Arias, Ana M Cabrera-Martinez, Victoria Úbeda-Vargas, Zulianni A Jiménez-Colmenárez, Joaquín Domínguez-Humanes, Lucía Gutiérrez-Ramírez, Rocío Juárez-Tosina, Javier Molina-Infante, Alfredo J Lucendo","doi":"10.18176/jiaci.1161","DOIUrl":"https://doi.org/10.18176/jiaci.1161","url":null,"abstract":"<p><strong>Background and objective: </strong>The prevalence of eosinophilic esophagitis (EoE) continues to increase, although nearly a decade has passed since the last reported epidemiological assessment in Spain. Objective: To update population-based estimates of incidence, prevalence, and trends in EoE among children and adults.</p><p><strong>Methods: </strong>A population-based study was conducted between 2006 and 2024 in 2 Spanish EoE units. Cases were retrieved from the EoE CONNECT database; pathology databases were also consulted to ensure exhaustive data inclusion. Diagnosis of EoE was confirmed with symptoms of esophageal dysfunction and eosinophilia ≥15/HPF. Annual incidence rates and prevalence with 95%CIs were standardized to each area population.</p><p><strong>Results: </strong>A total of 563 patients were treated during 2006-2024 (243 at Tomelloso General Hospital [50 children] and 320 at Hospital Universitario de Caceres). The average incidence in children was 15.74 (95%CI, 11.3-20.3) new cases/100 000 inhabitants/year for the whole study period, peaking at 23.95 (95%CI, 16.9-32.5) during the last decade. The prevalence of pediatric EoE in 2024 was 143.6 (95%CI, 88.1-215.4)/100 000 inhabitants. The average incidence for adults at Tomelloso for the whole period was 11.49 (95%CI, 9.9-13.2) new cases/100 000 inhabitants/year, with prevalence in 2024 reaching 251.39 (95%CI, 219.3-287.1) cases/100 000 inhabitants. The incidence in Caceres was 9.41 (95%CI, 8.3-10.5)/100 000 inhabitants, increasing markedly throughout the period, with prevalence in 2024 at 194.73 (95%CI, 175-216.8) cases/100 000 inhabitants. All prevalence figures doubled prior estimates from 2016-2017.</p><p><strong>Conclusion: </strong>EoE is growing sharply and steadily and is increasingly considered a chronic disorder. Its prevalence has doubled in both children and adults in less than a decade in Spain.</p>","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"0"},"PeriodicalIF":4.8,"publicationDate":"2026-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147576166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Experience With Dupilumab in Severe Asthma: The Spanish Multicenter Study DUPImpact.","authors":"Hemily Izaguirre-Flores, Ebymar Arismendi, Elena Martín-Ruiz de la Rosa, Berta Román-Bernal, Irene De Lorenzo-García, Inmaculada Plasencia-García, Annety Juanes-Olite, Candelaria Martín-García, Yurena Hernández Galván, Cristina Bellver-Asperilla, Alberto García-De la Fuente, Carlos Cabrera-López, Mariana Muñoz-Esquerre","doi":"10.18176/jiaci.1156","DOIUrl":"https://doi.org/10.18176/jiaci.1156","url":null,"abstract":"<p><strong>Background and objective: </strong>Dupilumab has proven effective in asthma in clinical trials, although real-world evidence remains limited. While tools such as FEOS and EXACTO may aid in evaluating effectiveness, evidence supporting their use remains scarce. Objective: To evaluate the real-world effectiveness of dupilumab in a Spanish cohort of patients with uncontrolled severe type 2 (T2) asthma.</p><p><strong>Methods: </strong>DUPImpact was a retrospective, multicenter study including adults with severe uncontrolled T2 asthma treated with dupilumab in 7 Spanish hospitals. Clinical outcomes were evaluated at 6 and 12 months and included the annual exacerbation rate (AER), asthma control (Asthma Control Test [ACT]), lung function (FEV1), and maintenance oral corticosteroid (OCS) use. Response was quantified using the FEOS and EXACTO scales.</p><p><strong>Results: </strong>The study population comprised 94 patients, of whom most had previously received biologics and 16% were OCS-dependent. After 12 months, AER decreased significantly, asthma control improved for most patients (ACT ≥20), and the mean increase in FEV1 was >300 mL. The number of patients receiving maintenance OCS decreased from 15 to 5, and the mean daily dose tended to decrease (not significant). According to the FEOS and EXACTO scales, over 70% of patients were classified as good responders, with 31% classified as super-responders.</p><p><strong>Conclusions: </strong>The DUPImpact study confirms the real-world effectiveness of dupilumab in reducing exacerbations and OCS use and improving asthma control and lung function. FEOS and EXACTO enable a multidimensional assessment beyond individual measures.</p>","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"0"},"PeriodicalIF":4.8,"publicationDate":"2026-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147576088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Tolerability of Bilastine 0.6% Ophthalmic Solution in Children and Adolescents: An 8-Week Phase 3 Study.","authors":"Teresa Garriga-Baraut, Clara Padró-Casas, Adelaida Sánchez Bacallao, Pablo Durán-Pérez, Eva M Lasa Luaces, Porfirio Fernández González, Amalia Leceta, Cristina Martínez Ostalé, Inmaculada Gilaberte","doi":"10.18176/jiaci.1169","DOIUrl":"https://doi.org/10.18176/jiaci.1169","url":null,"abstract":"<p><strong>Background and objective: </strong>Preservative- and phosphate-free bilastine ophthalmic solution with sodium hyaluronate provides additional benefits for ocular surface protection and hydration compared with second-generation antihistamines. These advantages are especially relevant for long-term pediatric treatment, although no previous study has evaluated the safety of the solution in this population. Objective: To evaluate the safety and tolerability of preservative-free bilastine 0.6% ophthalmic solution after 8 weeks of once-daily administration in children and adolescents with allergic conjunctivitis.</p><p><strong>Methods: </strong>This multicenter, randomized, double blind, placebo-controlled, parallel-group, phase 3 study included patients aged >2 to <18 years who were randomized 2:1 to receive bilastine or placebo for 8 weeks. The primary endpoint was the incidence of ocular-related treatment-emergent adverse events (ocular r-TEAEs).</p><p><strong>Results: </strong>Sixty-five patients were enrolled, and 59 were randomized: 42 to bilastine and 17 to placebo. No ocular r-TEAEs occurred in bilastine-treated patients (0/42 [95%CI, 0.0%-8.4%]), while 1 was reported in a placebo-treated patient (1/17 [95%CI, 1.1%-27.0%]). The overall incidence of ocular TEAEs was similar in both groups (bilastine 16.7% [95%CI, 8.3%-30.6%]; 7/42; placebo 17.6% [95%CI, 6.2%-41.0%]; 3/17). No serious or severe TEAEs occurred. Moderate TEAEs were reported in 4.8% (2/42, 95%CI, 1.3%-15.8%) of bilastine patients and 5.9% (1/17, 95%CI, 1.1-27.0%) of placebo patients. Most participants reported no or only slight ocular symptoms or discomfort after instillation, both at baseline and after 8 weeks.</p><p><strong>Conclusions: </strong>Preservative- and phosphate-free bilastine 0.6% ophthalmic solution with sodium hyaluronate was safe and well-tolerated in pediatric patients aged >2 years after a once-daily, 8-week treatment, with a safety profile comparable to that of placebo.</p>","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"0"},"PeriodicalIF":4.8,"publicationDate":"2026-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147534037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a Panel of Molecular Biomarkers of Asthma: Analysis of Differential Expression and Stability Over Time.","authors":"Lucía Cremades-Jimeno, María López-Ramos, Selen Baos, Rubén Fernández-Santamaría, María A de Pedro, Ignacio Mahíllo-Fernández, Cristina Rosales-Ariza, José M Olaguibel, Victoria Del Pozo, María L Caballero, Juan A Luna-Porta, Santiago Quirce, Blanca Barroso, Diana Betancor, Marcela Valverde-Monge, Joaquín Sastre, Blanca Cárdaba","doi":"10.18176/jiaci.1168","DOIUrl":"https://doi.org/10.18176/jiaci.1168","url":null,"abstract":"<p><strong>Background: </strong>Asthma is a chronic inflammatory respiratory disease characterized by significant heterogeneity, which complicates accurate patient classification and management. With the aim of defining new, reliable biomarkers, we previously evaluated the potential of 94 genes to differentiate allergic asthma (AA) from nonallergic asthma (NA) based on their expression in peripheral blood mononuclear cells (PBMCs). Here, the most promising biomarkers were further analyzed in a 2-year longitudinal cohort of 24 healthy controls (HCs), 18 NA patients, and 51 AA patients.</p><p><strong>Methods: </strong>PBMC samples were collected at the beginning of the study (T0) and 2 years later (T2). The expression of 26 genes was analyzed using RT-qPCR. Genes showing stable expression over time (ie, with a high correlation between T0 and T2) were selected for further analysis. Differential expression and receiver operating characteristic (ROC) curve analysis were used to identify the best biomarkers for discrimination between phenotypes.</p><p><strong>Results: </strong>Longitudinal stability was good for 13 genes. Of these, 11 showed statistically significant differential expression between asthma patients and HCs. ROC curve analyses were used to rank these genes by their discriminatory power. Specifically, CPA3 expression was able to discriminate asthma patients from HCs, while LGALS3 and TGFß1 made it possible to differentiate between NA and AA. Additionally, asthma severity was assessed based on the expression levels of RNASE3, IL4R, CHI3L1, PI3, and IL1R2.</p><p><strong>Conclusions: </strong>We propose a diagnostic algorithm based on the expression profiles of 8 genes in PBMCs that could guide clinicians in the diagnosis and phenotypic classification of asthma.</p>","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"0"},"PeriodicalIF":4.8,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147516443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of Life and Potential Biomarkers in Different Phenotypes of Chronic Rhinosinusitis With Nasal Polyps (CRSwNP).","authors":"Mauricio López-Chacón, María J Rojas-Lechuga, Marina Bantulà, Maria Barros, Cristóbal Langdon, Concepció Marín, Joaquim Mullol, Isam Alobid","doi":"10.18176/jiaci.1132","DOIUrl":"https://doi.org/10.18176/jiaci.1132","url":null,"abstract":"<p><strong>Background and objectives: </strong>Chronic rhinosinusitis with nasal polyps (CRSwNP) significantly impairs quality of life (QOL), especially in individuals with comorbid asthma and nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD). The 22-item Sino-Nasal Outcome Test (SNOT-22) is a validated questionnaire for assessing QOL in these patients. Objectives: To evaluate the subjective burden of CRSwNP, CRSwNP with asthma, and N-ERD using SNOT-22 and investigate associations with serum chemokines and cytokines as biomarkers in a representative sample of individuals from the 3 phenotypes.</p><p><strong>Material and methods: </strong>This cross-sectional study analyzed data from 117 participants in the rhinology unit between 2015 and 2021. Symptoms and disease severity were evaluated (mean [SD]) using the visual analog scales (VAS), SNOT-22, Lund-Mackay score (LMS), nasal polyp score (NPS), and aeroallergen sensitization test (atopy). Serum levels of 17 cytokines and chemokines were measured using Luminex/ELISA.</p><p><strong>Results: </strong>The SNOT-22 (56.3 [22.5]), LMS (19.2 [4.9]), and NPS (5.3 [1.4]) scores were worse for the N-ERD phenotype than for CRSwNP with and without asthma. This group was the most affected in sinonasal severity VAS scores (P<.0500). Nasal obstruction and loss of smell were the most affected SNOT-22 domains and VAS symptoms, respectively (P<.0500). In N-ERD, NPS correlated positively with the total SNOT-22 score (coefficient values 6.51 and 10.9, P<.0500). Sex did not correlate with SNOT-22 scores (P=.1500). Higher serum levels of VEGF-A (P=.0460), TARC (P=.0378), and TSLP (P=.0491) were detected in the N-ERD group.</p><p><strong>Conclusion: </strong>SNOT-22 can be used to effectively assess QOL and differentiate between CRSwNP phenotypes, highlighting a greater burden in N-ERD patients. Biomarker analysis supports the distinct inflammatory profile of N-ERD.</p>","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"0"},"PeriodicalIF":4.8,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147437053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}